Application of Immunocompetent Microphysiological Systems in Drug Development : Current Perspective and Recommendations

被引:9
作者
Wang, Xiaoting [1 ,11 ]
Kopec, Anna K. [2 ]
Collinge, Mark [2 ]
David, Rhiannon [3 ]
Grant, Christian [4 ]
Hardwick, Rhiannon N. [5 ,6 ]
Navratil, Aaron [7 ]
Patel, Nirav [8 ]
Rowan, Wendy [9 ]
Marshall, Nikki B. [1 ,10 ,12 ]
机构
[1] Amgen Inc, Translat Safety & Bioanalyt Sci, Amgen Res, South San Francisco, CA USA
[2] Pfizer Inc, Drug Safety Res & Dev, Groton, CT USA
[3] AstraZeneca, Safety Innovat Clin Pharmacol & Safety Sci, R&D, Cambridge, England
[4] AbbVie Inc, Preclin Safety, Worcester, MA USA
[5] Theravance Biopharm US Inc, Translat Safety Sci, South San Francisco, CA USA
[6] Bristol Myers Squibb, Discovery Toxicol Preclin Candidate Optimizat, San Diego, CA USA
[7] Theravance Biopharm US Inc, Biol & Pharmacol, South San Francisco, CA USA
[8] Sanofi Aventis US LLC, Preclin Safety Res & Dev, Framingham, MA USA
[9] GSK, Novel Human Genet, Stevenage, England
[10] GSK, Nonclin Safety, Collegeville, PA USA
[11] Amgen Inc, 750 Gateway Blvd, Suite 100, South San Francisco, CA 94080 USA
[12] GSK, 1250 South Collegeville Rd, Collegeville, PA 19426 USA
关键词
ON-A-CHIP; ADAPTIVE IMMUNE-RESPONSES; HEMODYNAMIC SHEAR-STRESS; HUMAN HEMATOPOIETIC STEM; LUNG DENDRITIC CELLS; IN-VITRO MODELS; T-CELLS; BONE-MARROW; INDUCED THROMBOSIS; SKIN IRRITATION;
D O I
10.14573/altex.2205311
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Immune responses are heavily involved in the regulation and pathogenesis of human diseases, including infectious dis-eases, inflammatory and autoimmune conditions, cancer, neurological disorders, and cardiometabolic syndromes. The immune system is considered a double-edged sword serving as a powerful host defense mechanism against infection and cancerous cells and causing detrimental tissue damage when the immune response is exaggerated or uncontrollable. One of the challenges in studying the efficacy and toxicity of drugs that target or modulate the immune system is the lack of suitable preclinical human models that are predictive of human response. Recent advancements in human microphysiological systems (MPS) have provided a promising in vitro platform to evaluate the response of immune organs ex vivo, to investigate the interaction of immune cells with non-lymphoid tissue cells, and to reduce the reliance on animals in preclinical studies. The development, regulation, trafficking, and responses of immune cells have been extensively studied in preclinical animal models and clinically, providing a wealth of knowledge by which to evaluate new in vitro models. Therefore, the application of immunocompetent MPS in drug discovery and development should first verify that the immune response in an MPS model recapitulates the complexity of the human immune physiology. This manuscript reviews biological functions of immune organ systems and tissue-resident immune cells and discusses contexts-of-use for commonly used immunocompetent and immune organ MPS models. Current perspective and recommendations are provided to guide the continued development of immune organ and immunocompetent MPS models and their application in drug discovery and development.
引用
收藏
页码:314 / 336
页数:23
相关论文
共 182 条
  • [1] Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling
    Abaci, Hasan Erbil
    Shuler, Michael L.
    [J]. INTEGRATIVE BIOLOGY, 2015, 7 (04) : 383 - 391
  • [2] Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: a biopharmaceutical perspective
    Ainslie, Garrett R.
    Davis, Myrtle
    Ewart, Lorna
    Lieberman, Linda A.
    Rowlands, David J.
    Thorley, Andrew J.
    Yoder, Gorm
    Ryan, Anne M.
    [J]. LAB ON A CHIP, 2019, 19 (19) : 3152 - 3161
  • [3] Humanized immune system mouse models: progress, challenges and opportunities
    Allen, Todd M.
    Brehm, Michael A.
    Bridges, Sandra
    Ferguson, Stacy
    Kumar, Priti
    Mirochnitchenko, Oleg
    Palucka, Karolina
    Pelanda, Roberta
    Sanders-Beer, Brigitte
    Shultz, Leonard D.
    Su, Lishan
    PrabhuDas, Mercy
    [J]. NATURE IMMUNOLOGY, 2019, 20 (07) : 770 - 774
  • [4] Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption
    Allwardt, Vanessa
    Ainscough, Alexander J.
    Viswanathan, Priyalakshmi
    Sherrod, Stacy D.
    McLean, John A.
    Haddrick, Malcolm
    Pensabene, Virginia
    [J]. BIOENGINEERING-BASEL, 2020, 7 (03): : 1 - 27
  • [5] Microphysiological Engineering of Immune Responses in Intestinal Inflammation
    Ambrosini, Yoko M.
    Shin, Woojung
    Min, Soyoun
    Kim, Hyun Jung
    [J]. IMMUNE NETWORK, 2020, 20 (02)
  • [6] Anderson Graham, 2007, CSH Protoc, V2007, DOI 10.1101/pdb.prot4808
  • [7] Anderson Graham, 2007, Methods Mol Biol, V380, P185
  • [8] Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model
    Ando, Yuta
    Siegler, Elizabeth L.
    Ta, Hoang P.
    Cinay, Gunce E.
    Zhou, Hao
    Gorrell, Kimberly A.
    Au, Hannah
    Jarvis, Bethany M.
    Wang, Pin
    Shen, Keyue
    [J]. ADVANCED HEALTHCARE MATERIALS, 2019, 8 (05)
  • [9] Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials
    Atkins, Johnique T.
    George, Goldy C.
    Hess, Kenneth
    Marcelo-Lewis, Kathrina L.
    Yuan, Ying
    Borthakur, Gautam
    Khozin, Sean
    LoRusso, Patricia
    Hong, David S.
    [J]. BRITISH JOURNAL OF CANCER, 2020, 123 (10) : 1496 - 1501
  • [10] Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model
    Ayuso, Jose M.
    Truttschel, Regan
    Gong, Max M.
    Humayun, Mouhita
    Virumbrales-Munoz, Maria
    Vitek, Ross
    Felder, Mildred
    Gillies, Stephen D.
    Sondel, Paul
    Wisinski, Kari B.
    Patankar, Manish
    Beebe, David J.
    Skala, Melissa C.
    [J]. ONCOIMMUNOLOGY, 2019, 8 (03):